2022 Neurotech Leaders Forum

November 7-8, 2022

Embassy Suites, San Francisco Airport Waterfront and Zoom

Tentative Agenda (all times PST) 

Day One

8:00-8:30

Registration and Coffee

8:30-9:15

State of the Neurotechnology Industry: 2022

James Cavuoto, Editor and Publisher, Neurotech Reports
Neurotech Business Report Editor James Cavuoto provides his insights and observations on the state of the neurotechnology industry. He surveys changes in the competitive landscape that have occurred over the years, the most significant events of the last year, and challenges confronting the industry in years ahead.
9:15-10:00

Keynote Address

Mudit Jain, Ph.D., General Partner, Treo Ventures
10:00-10:30

Refreshment Break

10:30-11:15

Neurotech Investment Outlook: Is the Gold Rush Over?

Jeremy Koff, Senior Consulting Editor, Neurotech Reports, Moderator
Ariane Tom, Ph.D., Managing Director, Kaleida Capital
Suraj Mudichintala, Senior Associate, Action Potential Venture Capital
Amy Kruse, Ph.D., General Partner, Prime Movers Lab
Nick Langhals, Ph.D., Program Director for Translational Devices Programs, National Institutes of Health/NINDS
In the last few years, we've seen a considerable amount of VC investment in neurotech startups. But what will be the effect of more uncertain economic conditions? Our panel of investment professionals will offer their insights.
11:15-12:00

DBS Goes Deep: New Indications Emerge for Neuromodulation Therapies

Jennifer French, Senior Contributing Editor, Neurotech Reports, Moderator
Lothar Krinke, Ph.D., CEO, Newronika Spa
Erika Ross, Ph.D., Director, Clinical & Applied Research, Abbott Neuromodulation
Jacob Robinson, Ph.D., Co-Founder and CEO, Motif Neurotech
Once restricted to treating movement disorders such as Parkinson's disease, deep-brain stimulation now stands to penetrate a range of new disorders. Abbott's reentry in the depression market sends a strong signal that DBS will be a key therapy for treating psychiatric disorders. Our panel of experts will discuss the possibilities.   
12:00-1:30

Luncheon, Sponsored by Cirtec Medical

1:30-3:00

Neurotechnology Entrepreneur Panel

James Cavuoto, Editor, Neurotech Reports, Moderator
Byoung Kwan Kim, CEO, gBrain
Luca Ravagnan, Ph.D., CEO, WISE Srl
Ingrid van Welie, Ph.D., CEO, Neural Dynamics Technologies
Perry Teevens, Ph.D., CEO and Co-Founder, REVAI
Krishnan Chakravarthy, M.D., Ph.D., Founder and CEO, NXTStim
This session features presentations from CEOs and executives of several neurotechnology start-up firms and more established technology ventures. Each executive will present an overview of their firm's technology and markets.
3:00-3:30

Refreshment Break

3:30-4:15

Sacred Ground: Privacy, Security, and Ethics in Neurotech

Jo Jo Platt, Contributing Editor, Neurotech Reports, Moderator
Marcus Gerhardt, CEO, Blackrock Neurotech
Rob Barnes, Principal Consultant, Amazon Web Services
Anna Wexler, Assistant Professor, Medical Ethics and Health Policy, University of Pennsylvania School of Medicine
This panel features a roundtable discussion to help investors evaluate a technology, founders to learn what's expected, and developers to understand the considerations that need to be baked in to every device.
4:15-5:00

Overcoming Bias: Neurotech Therapies Seek to Penetrate Pharma Markets

James Cavuoto, Editor, Neurotech Reports, Moderator
Marco Sorani, Ph.D., Executive Director, Development Sciences, Genentech, Inc.
Eric Hsu, Partner, Wilson Sonsini
Victor Pikov, Ph.D., CEO, Medipace, Inc.
The recent controversy surrounding failed drug trials for Alzheimer's and the dubious claims of the amyloid hypothesis highlights some of the bias neuromodulation vendors have had to confront when trying to penetrate a market dominated by big pharma. In this session, we'll explore some of the strategies device firms can employ to overcome the inherent bias that still exists.
5:00-7:00

Cocktail Reception, Sponsored by MST

 
 

 

Day Two

8:00:8:30

Registration and Coffee

8:30-9:15

Facing the Public: An Editorial Perspective

James Cavuoto, Editor and Publisher, Neurotech Reports, Moderator
Jeremy Koff, Senior Consulting Editor, Neurotech Reports
Jo Jo Platt, Contributing Editor, Neurotech Reports
In this session, Neurotech Reports team of editors will offer their views on recent controversies facing the neuromodulation industry, including ethical concerns, dealing with bad press, and legislative and regulatory developments.
9:15-10:00

Using Our Head: Wearable Brain Devices Exploit New Market Opportunity

The market for noninvasive brain sensing and brain stimulation headsets is poised for growth as users and clinicians seek to exploit expanded knowledge of neural circuits and targets. In this session, three vendors of wearable headsets will describe their technology and market opportunity.
Richard Hanbury, CEO and Founder, Sana Health
Iain McIntyre, Head of Marketing, Roga Life
Israel Gasperin, CEO and Founder, Zentrela, Inc.
10:00-10:30

Coffee Break

10:30-11:15

Reimbursement Outlook: CMS Opens the Door for Neurotech Therapies 

Jeremy Koff, Senior Consulting Editor, Neurotech Reports, Moderator
James Makous, Ph.D., Principal, Makous Research, LLC
Chris Hanna, CEO, Pacific Therapy Access
After a disappointing decision to repeal the Medicare Coverage of Innovative Technology program, CMS has offered guidance on constructing a replacement that would achieve similar results. And the several new codes for implanted and noninvasive therapies have emerged to help shorten the commercialization path for neurotech startups. Our panel of experts will discuss the reimbursement outlook for neurotech in this session.
11:15-12:00

Fixing What's Broke: Neurorehabilitation Devices Reach the Market

Jo Jo Platt, Contributing Editor, Neurotech Reports, Moderator
Jeremiah Robison, Founder and CEO, Cionic
Richard Foust, CEO, MicroTransponder, Inc.
Jennifer French, Executive Director, Neurotech Network
When the FDA approved MicroTransponder's Vivistim stroke therapy last year, it ended the drought that followed the Northstar EVEREST trial failure in 2009. In this panel, we'll examine some of the many new implantable and wearable neurorehabilitation therapies reaching the market.
12:00-1:30

Luncheon, Sponsored by Cirtec Medical

Presentation of 2022 Gold Electrode Awards
1:30-3:00

Neurotechnology Entrepreneur Panel

James Cavuoto, Editor, Neurotech Reports, Moderator
Yi-Kai Lo, Ph.D., CEO, Aneuvo
Colin Kealey, M.D., President, NeuroSigma
Nader Yaghoubi, M.D., Ph.D., President and CEO, PathMaker Neurosystems Inc.
Aswin Gunasekar, CEO and Founder, Zeto Inc.
3:00-3:30

Refreshment Break

3:30-4:15

Reinventing the Wheel: Neurotech Startups Outsource Key Components 

James Cavuoto, Editor, Neurotech Reports, Moderator
Andrew Kelly, Director of Applications Engineering, Cirtec Medical
Hannah Claridge, Ph.D., Head of Neurotechnology, The Technology Partnership plc
Peter Putnam, Regional Manager, Micro Systems Technologies, Inc.
Neurotech startups can save a considerable amount of time and expense by taking advantage of suppliers of key components such as power sources, interconnects, enclosures, and leads. In this session, we'll discuss the tradeoffs that entrepreneurs and their investors confront when making build or buy decisions. 
4:15-5:00

Spreading the Pain: Neuromodulation Vendors Stake Out New Ground 

Jeremy Koff, Senior Consulting Editor, Neurotech Reports, Moderator
Manfred Franke, Ph.D., CEO, Neuronoff Inc.
Ramana Naidu, M.D., Pain Physician and Anesthesiologist, California Orthopedics and Spine
Devjani Saha, Ph.D., Director, Neurology Regulatory Affairs, MCRA
The market for treating chronic pain continues to be the largest segment of the neuromodulation industry, but vendors of SCS, PNS, and noninvasive devices are offering numerous therapeutic options for treating different types of pain. In this session, we'll explore the outlook for new targets and stimulation regimens.
5:00-7:00

Cocktail Reception, Sponsored by MST

 
 

 

      

©2022 Neurotech Reports. All rights reserved.